Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives $5.92 Average PT from Analysts

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have earned a consensus rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $5.92.

Several research firms have recently issued reports on XERS. Piper Sandler reissued a “neutral” rating and issued a $4.00 price objective (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum upped their price target on shares of Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a research report on Friday, March 7th. Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, March 7th.

Xeris Biopharma Stock Up 5.7 %

NASDAQ:XERS opened at $4.82 on Monday. The company has a market cap of $741.99 million, a P/E ratio of -10.71 and a beta of 2.32. The firm’s 50 day moving average is $3.68 and its two-hundred day moving average is $3.31. Xeris Biopharma has a fifty-two week low of $1.69 and a fifty-two week high of $4.90.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in XERS. Legato Capital Management LLC bought a new stake in shares of Xeris Biopharma in the 4th quarter worth approximately $482,000. Barclays PLC boosted its holdings in shares of Xeris Biopharma by 87.8% during the third quarter. Barclays PLC now owns 324,472 shares of the company’s stock valued at $925,000 after acquiring an additional 151,685 shares during the period. Geode Capital Management LLC grew its position in shares of Xeris Biopharma by 2.9% during the third quarter. Geode Capital Management LLC now owns 3,333,470 shares of the company’s stock worth $9,502,000 after acquiring an additional 93,091 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of Xeris Biopharma by 30.3% in the 3rd quarter. Principal Financial Group Inc. now owns 102,469 shares of the company’s stock worth $292,000 after acquiring an additional 23,843 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Xeris Biopharma in the 3rd quarter worth about $44,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.